Building the Foundations for Successful Live Cell Assays in Global Clinical Trials
Building the Foundations for Successful Live Cell Assays in Global Clinical Trials
Live cell assays play a critical role in clinical research, particularly in the assessment of immune system responses, drug efficacy, and safety. When designing these assays for global clinical trials, several foundational elements must be considered to ensure the reliability, accuracy, and scalability of the results. This article delves into the key components of setting up live cell assays for clinical trials, including assay objectives, logistics, sample collection and processing, and the critical importance of control mechanisms.
Defining the Assay Objectives
One of the first and most important steps in setting up live cell assays is defining the assay objectives. While this may seem like a straightforward task, the assay’s objective directly influences critical decisions, including matrix and stimulant selection, as well as sample logistics. For example, functional assays, which assess immune responses, include techniques such as intracellular cytokine staining (ICS), ELISpot, and cytotoxicity assays. These assays require precise timing, as sample processing and analysis must occur quickly—ideally within 8 hours of sample collection. This narrow time window can present significant logistical challenges for clinical trials, particularly in remote or regional trial sites.
Additionally, whereas immunophenotyping assays may provide greater flexibility in terms of sample processing due to longer antigen stability windows, these assays still require careful planning to ensure the timing of sample collection aligns with the assay requirements. They also require a careful assessment of the impact of the collection method, including methods of cell isolation and freezing, to ensure resolution and stability of the target antigen(s).
Addressing Logistics and Sample Stability
The logistics for processing and analyzing samples in live cell assays are crucial considerations. Functional assays, which may need to be processed within 8 hours, require the use of regional or clinical collection sites, as they cannot be delayed for long shipping times to central labs. This could involve additional training for clinical staff and the provision of specialized equipment at these sites. For assays with a longer antigen stability window, such as phenotyping assays, samples can often be shipped overnight to central labs for processing, as long as they are within the validated stability window.
Understanding the specific timelines for sample processing is key when selecting clinical trial sites and ensuring that sample handling processes align with assay objectives. For instance, assays that allow for a longer stability window (e.g., 24 to 36 hours) may allow for more flexibility in the shipment of samples. In contrast, functional assays require the samples to be processed rapidly, necessitating careful planning to ensure that these samples are analyzed promptly, potentially even at the clinical collection site itself.
Matrix and Sample Collection Protocols
Live cell assays rely heavily on the selection of the appropriate sample matrix, with whole blood and peripheral blood mononuclear cells (PBMCs) being the most commonly used matrices in these assays. The choice of matrix and the procedure for sample collection and processing are critical factors in ensuring the reliability of assay results.
- Whole Blood: When working with whole blood, it is important to choose the appropriate anticoagulant to preserve cell function. If the assay requires shipping the samples to a central lab, the sample must remain stable during transit. For samples that need to be stored longer, whole blood can be frozen using methods such as fetal bovine serum (FBS) or synthetic freezing media, as well as fixative-based freezing solutions. These methods may help to expedite the processing time to avoid loss of stability during transport and storage. Fresh whole blood remains a gold standard for assessing live cells, and all alternative approaches should be carefully assessed to ensure that they meet the requirements of the study.
- PBMCs: PBMCs offer advantages for batching samples, as they can be isolated and stored more efficiently than whole blood. However, successful PBMC isolation requires careful attention to timing and antigen stability, as well as well trained staff performing the isolation. Once isolated, PBMCs need to be processed using appropriate freezing and thawing protocols that are compatible with the downstream assay methods.
Both whole blood and PBMC-based assays require careful attention to the matrix stability, timing, and processing methods to ensure that antigen stability is preserved throughout the duration of the clinical trial.
Assay Controls: Ensuring Accuracy and Consistency
For live cell assays to generate reliable results, it is essential to incorporate appropriate controls. This ensures that assays are performing as expected and helps support the clinical trial’s goals. Control strategies vary between phenotyping and functional assays, but both types of assays benefit from the inclusion of multiple controls.
- Functional Assays: In functional assays, controls are essential to assess whether the cells are behaving as expected. Generic controls, such as T-cell receptor (TCR) cross-linkers like phytohemagglutinin (PHA) or staphylococcal enterotoxin B (SEB), can be used to confirm cellular functionality. Antigen-specific controls, such as viral peptide pools, are often employed to assess TCR engagement and the effectiveness of antigen presentation. A critical aspect of functional assays is ensuring a low background, indicating that the cells have been properly isolated and are in optimal condition for analysis.
- Sample Collection Monitoring: Throughout the clinical trial, it is vital to monitor the consistency of sample collection across different sites. Incorporating donor validation into the process allows researchers to track the consistency of sample collection and processing. In addition, quality control parameters and accepatance criteria should be incorporated into the assay to help identify and flag any sample integrity issues. This helps identify any potential issues and ensures that all samples meet the necessary criteria for reliable assay results.
Conclusion
Setting up live cell assays for global clinical trials requires careful planning and attention to detail. From defining assay objectives and selecting the appropriate matrices to addressing logistics, stability, and controls, each decision can significantly impact the success of the trial. At Eurofins Clinical Trial Solutions, we can help you build a solid foundation that supports the integrity and reliability of live cell assays by considering the timing of sample collection, the logistics of processing and shipping, and the necessary assay controls. These efforts ensure that your clinical trial runs smoothly and yields meaningful results, ultimately contributing to the advancement of medical knowledge and the development of new therapies.
Learn more about Eurofins Clinical Trial Solutions’ cell-based assay capabilities.